- Summary
- Table Of Content
- Methodology
ACE Inhibitors Market Size:
ACE Inhibitors market size is estimated to reach over USD 9.78 Billion by 2031 from a value of USD 6.70 Billion in 2023 and is projected to grow by USD 6.91 Billion in 2024, growing at a CAGR of 4.8% from 2024 to 2031.
ACE Inhibitors Market Scope & Overview:
ACE inhibitors, or angiotensin-converting enzyme inhibitors, are a class of medications primarily used to treat high blood pressure, heart failure, and certain kidney diseases. These medications work by blocking the enzyme that produces angiotensin II, a substance that narrows blood vessels, leading to increased blood pressure. By inhibiting this enzyme, ACE inhibitors help relax blood vessels, reduce blood pressure, and improve the efficiency of the heart. They are commonly prescribed for patients with cardiovascular conditions and are known to reduce the risk of strokes, heart attacks, and other complications related to hypertension. The healthcare sector, particularly hospitals and clinics, relies on these medications to manage chronic conditions effectively. End-use industries such as pharmaceuticals and healthcare providers are key drivers of the market, with ongoing research aimed at improving the efficacy and safety of these medications.
ACE Inhibitors Market Dynamics - (DRO) :
Key Drivers:
Rising Prevalence of Hypertension and Cardiovascular Diseases Propels the Market
The growing global prevalence of hypertension and cardiovascular diseases is a key driver of the ACE inhibitors market growth. ACE inhibitors, which work by relaxing blood vessels and reducing blood pressure, are widely prescribed for the treatment of hypertension, heart failure, and chronic kidney diseases. With the increasing incidence of lifestyle-related diseases such as obesity, diabetes, and high cholesterol, the demand is expanding, particularly in developed regions like North America and Europe where the aging population is more susceptible to these conditions. Additionally, the global shift toward preventive healthcare and early intervention strategies is further driving the use of these inhibitors in managing high blood pressure and reducing the risk of severe cardiovascular events such as heart attacks and strokes.
Key Restraints :
Emergence of Alternative Therapies and Associated Side Effects Hinders the Market
One of the primary restraints in the market is the growing competition from alternative treatments, including angiotensin II receptor blockers (ARBs) and direct renin inhibitors, which offer similar therapeutic benefits but with fewer side effects. ACE inhibitors are associated with adverse effects such as cough, hyperkalemia, and angioedema, which can limit patient adherence and lead to treatment discontinuation. Moreover, the introduction of newer therapies with improved safety profiles, such as ARBs, is causing a gradual shift in prescribing patterns among healthcare providers. The increasing preference for these alternatives, especially in patients who experience significant side effects with these inhibitors, is hindering the ACE inhibitors market growth.
Future Opportunities :
Expansion in Emerging Markets and Combination Therapies Opens New Doors
Emerging markets in Asia-Pacific, Latin America, and the Middle East present significant ACE inhibitors market opportunities. The rising incidence of hypertension in these regions, driven by urbanization, changing lifestyles, and growing healthcare awareness, is increasing the demand for affordable and effective treatments. Moreover, the development of combination therapies, where these inhibitors are paired with other antihypertensive agents such as diuretics or calcium channel blockers, is gaining traction as it offers enhanced efficacy with improved patient compliance. These combination therapies are particularly valuable in managing comorbid conditions in patients with multiple cardiovascular risk factors, creating a broader scope for market expansion.
ACE Inhibitors Market Segmental Analysis :
By Drug Type:
Based on drug type, the market is segmented into captopril, enalapril, lisinopril, ramipril, fosinopril, quinapril, benazepril, and others.
The lisinopril segment accounted for the largest revenue of the total ACE inhibitors market share in 2023.
- Lisinopril is one of the most widely prescribed ACE inhibitors, particularly for managing hypertension and heart failure.
- Its once-daily dosing regimen, combined with its well-documented efficacy and safety profile, has made it the preferred option for many healthcare providers.
- Lisinopril is commonly prescribed for long-term management of hypertension, chronic kidney disorders, and heart failure, which has contributed to its widespread use.
- The growing prevalence of cardiovascular diseases (CVDs) and chronic kidney disease (CKD) has further bolstered the demand for lisinopril in recent years, making it the leading drug in this segment.
- Thus, as per the segmental trends analysis, Lisinopril dominates the market due to its proven efficacy in treating hypertension and heart failure, along with its widespread use in managing chronic conditions like CKD, boosting the ACE inhibitors market demand.
The ramipril segment is anticipated to register the fastest CAGR during the forecast period.
- Ramipril is increasingly favored for its broad therapeutic applications, including hypertension, heart failure, and myocardial infarction.
- It is particularly noted for its cardioprotective effects, especially in patients at high risk of cardiovascular events.
- As more clinical studies validate the efficacy of ramipril in preventing cardiovascular-related mortality, its adoption is rising among healthcare providers.
- Additionally, its long-acting nature and convenient dosing contribute to its growing popularity.
- The increasing global burden of CVDs and rising awareness among healthcare providers about preventive treatments are expected to drive the demand for ramipril over the coming years.
- The ACE inhibitors market analysis shows that Ramipril is expected to grow rapidly due to its proven cardioprotective benefits and rising use in preventive cardiovascular therapies, particularly among high-risk patient groups.
By Application:
Based on application, the market is segmented into hypertension, congestive heart failure (CHF), chronic kidney disorders, cardiovascular diseases (CVDs), and others.
The hypertension segment accounted for the largest revenue share of 45.15% in 2023.
- Hypertension remains the most prevalent condition for which ACE inhibitors are prescribed, as these medications effectively lower blood pressure by relaxing blood vessels.
- The global increase in sedentary lifestyles, unhealthy diets, and aging populations has contributed to the rise in hypertension cases, particularly in developed regions such as North America and Europe.
- ACE inhibitors are considered a first-line therapy for hypertension management, and their use has expanded significantly due to the increasing recognition of the link between hypertension and other severe conditions like stroke and myocardial infarction.
- As per the segmental trends analysis depicts that hypertension leads the market due to the rising global prevalence of the condition and the established role of ACE inhibitors as a first-line treatment option, driving the ACE inhibitors market growth.
The chronic kidney disorders (CKD) segment is anticipated to register the fastest CAGR during the forecast period.
- ACE inhibitors are widely used to manage chronic kidney disorders, particularly in patients with diabetes or hypertension, as they help reduce proteinuria and slow the progression of kidney damage.
- With the increasing incidence of diabetes and hypertension globally, the prevalence of CKD has surged, creating a greater need for effective management strategies.
- The ability of these inhibitors to protect kidney function, especially in diabetic nephropathy, has driven their growing use in nephrology.
- As awareness of the benefits of early CKD management rises, the demand for ACE inhibitors in this application is expected to increase significantly.
- Thus, the market trends analysis shows that the CKD segment is projected to grow rapidly, driven by the rising global incidence of diabetes and hypertension, and the well-established role of ACE inhibitors in preserving kidney function, boosting the ACE inhibitors market trends.
By Route of Administration:
Based on route of administration, the market is segmented into oral and intravenous.
The oral segment accounted for the largest revenue of the overall ACE inhibitors market share in 2023.
- Oral administration remains the most common route for ACE inhibitors, primarily because of the convenience, cost-effectiveness, and ease of compliance for patients.
- Most ACE inhibitors, including popular drugs like lisinopril and ramipril, are available in oral formulations that offer reliable bioavailability and consistent therapeutic effects.
- Oral administration is particularly favored in the long-term management of chronic conditions like hypertension, heart failure, and CKD, making it the preferred route in outpatient settings.
- The widespread availability of oral formulations across various healthcare systems has contributed to this segment's leading position.
- Thus, the market trends analysis shows that oral administration dominates the market due to its convenience and widespread use in the long-term management of chronic conditions such as hypertension and heart failure, driving the ACE inhibitors market expansion.
The intravenous segment is anticipated to register the fastest CAGR during the forecast period.
- Intravenous ACE inhibitors are typically used in acute care settings, such as hospitals, where rapid therapeutic effects are needed.
- This route of administration is particularly useful in emergencies, such as hypertensive crises or acute heart failure, where immediate control of blood pressure is critical.
- As hospitals and emergency care settings continue to advance in their capabilities for managing acute cardiovascular events, the demand for these inhibitors is expected to grow.
- Additionally, the increasing incidence of hypertensive emergencies and acute heart failure cases globally will drive this segment's expansion.
- Thus, the segment trends shows that Intravenous ACE inhibitors are expected to grow rapidly due to their critical role in acute care settings for managing emergencies such as hypertensive crises and acute heart failure, boosting the ACE inhibitors market trends.
By Distribution Channel:
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share in 2023.
- Hospital pharmacies are the primary distribution channel for ACE inhibitors in acute care settings, particularly for patients receiving intravenous administration or those undergoing cardiovascular procedures.
- Hospital pharmacies are also key suppliers of medications for inpatients with chronic conditions, such as heart failure and CKD, who require specialized care.
- With the rising incidence of cardiovascular diseases and hospital admissions related to hypertension and heart failure, the demand for ACE inhibitors through hospital pharmacies has increased significantly, solidifying this segment's dominant position.
- As per the market trends, hospital pharmacies lead the market as the primary distribution channel for ACE inhibitors, particularly for inpatients and those requiring specialized acute or chronic care.
The online pharmacies segment is anticipated to register the fastest CAGR during the forecast period.
- The growing trend of online pharmacies is driven by increasing patient preference for convenience, particularly in regions where healthcare access may be limited or where long-term prescriptions for chronic conditions like hypertension are common.
- The expansion of e-commerce in the pharmaceutical industry, coupled with rising internet penetration and improved delivery logistics, has made online pharmacies a rapidly growing distribution channel.
- Additionally, the availability of discounts and direct delivery options enhances the attractiveness of this segment, particularly for long-term users.
- As per the ACE inhibitors market analysis, online pharmacies are expected to grow rapidly as patients increasingly seek convenient, cost-effective access to ACE inhibitors for the long-term management of chronic conditions like hypertension and heart failure.
Regional Analysis:
The regions covered are North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
Asia Pacific region was valued at USD 1.36 Billion in 2023. Moreover, it is projected to grow by USD 1.42 Billion in 2024 and reach over USD 2.24 Billion by 2031. Out of this, China accounted for 36% of the total market share. Asia-Pacific is the fastest-growing region for the market, with countries like China, India, and Japan leading due to their large populations and rising incidence of cardiovascular diseases. Rapid urbanization, changes in lifestyle, and increasing rates of obesity and diabetes have contributed to the surge in hypertension cases, driving demand. Growing healthcare investments and expanding access to pharmaceuticals in these countries also propel market growth. However, lack of awareness and limited healthcare infrastructure in rural areas remain significant challenges.
North America is estimated to reach over USD 4.08 Billion by 2031 from a value of USD 2.75 Billion in 2023 and is projected to grow by USD 2.84 Billion in 2024. North America holds the largest share of the market, driven by the high prevalence of hypertension and cardiovascular diseases, especially in the U.S. The region benefits from a well-established healthcare infrastructure and a large aging population, contributing to the demand for ACE inhibitors as a first-line treatment for hypertension. Additionally, the high awareness of cardiovascular health and the availability of advanced pharmaceuticals support market growth. However, rising healthcare costs and the increasing availability of generic alternatives may slow ACE inhibitors market expansion.
Europe is a key market, with countries like Germany, the UK, and France leading in the adoption of cardiovascular treatments. The high incidence of hypertension and related cardiovascular conditions, especially among the elderly population, drives demand in the region. Governments and healthcare systems in Europe focus heavily on preventive care and management of chronic diseases, which supports the market. However, stringent regulations and the growing preference for alternative therapies such as angiotensin receptor blockers (ARBs) may limit growth.
The Middle East & Africa region is seeing steady growth in the market, particularly in countries like Saudi Arabia, the UAE, and South Africa. Rising rates of hypertension and cardiovascular diseases due to changing lifestyles, coupled with government initiatives to improve healthcare access, are driving demand for ACE inhibitors. Saudi Arabia and the UAE have been focusing on cardiovascular health as part of broader healthcare reforms. However, limited access to advanced healthcare facilities and medications in some parts of Africa continues to hinder ACE inhibitors market potential.
Latin America is an emerging market, with Brazil and Mexico being the major contributors. The region's growth is driven by the increasing prevalence of cardiovascular diseases, partly due to rising obesity and diabetes rates. Governments in these countries are emphasizing preventive healthcare, which supports the demand for antihypertensive medications like ACE inhibitors. However, economic instability and limited healthcare budgets in some countries may slow market growth.
Top Key Players & Market Share Insights:
The ACE inhibitors market is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the global ACE inhibitors market. Key players in the ACE Inhibitors industry include-
- Pfizer Inc. (USA)
- Novartis International AG (Switzerland)
- Merck & Co., Inc. (USA)
- Sanofi S.A. (France)
- Johnson & Johnson (USA)
- AstraZeneca (UK)
- Bristol-Myers Squibb Company (USA)
- Abbott Laboratories (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Mylan N.V. (USA)
Recent Industry Developments :
Approvals:
- In July 2022, Solco Healthcare, a subsidiary of Prinston Pharmaceutical, Inc., along with Zhejiang Huahai Pharmaceutical, announced that their Enalapril Maleate tablets (available in 2.5mg, 5mg, 10mg, and 20mg) received approval from the U.S. Food and Drug Administration (FDA). These tablets are AB-rated equivalents of Vasotec, produced by Bausch Health.
- In 2021, Sanofi received regulatory clearance for a new ACE inhibitor that features enhanced tolerability and effectiveness. With this approval, the company can now offer an advanced treatment option for patients suffering from heart failure and hypertension.
Product Launch:
- In February 2022, Camber Pharmaceuticals announced the launch of Enalapril Maleate Oral Solution, a generic version of Epaned, which is indicated for lowering blood pressure in both adults and children over one month of age.
ACE Inhibitors Market Report Insights :
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 9.78 Billion |
| CAGR (2024-2031) | 4.8% |
| By Drug Type |
|
| By Application |
|
| By Distribution Channel |
|
| By Route of Administration |
|
| By Region |
|
| Key Players |
|
| North America | U.S. Canada Mexico |
| Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
| APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
| Middle East and Africa | GCC Turkey South Africa Rest of MEA |
| LATAM | Brazil Argentina Chile Rest of LATAM |
| Report Coverage |
|
Key Questions Answered in the Report
What is the projected size of the ACE Inhibitors Market? +
ACE Inhibitors market size is estimated to reach over USD 9.78 Billion by 2031 from a value of USD 6.70 Billion in 2023 and is projected to grow by USD 6.91 Billion in 2024, growing at a CAGR of 4.8% from 2024 to 2031.
What are ACE inhibitors used for? +
ACE inhibitors are primarily used to treat hypertension (high blood pressure), heart failure, and chronic kidney diseases. They work by relaxing blood vessels, making it easier for the heart to pump blood, which helps reduce blood pressure and prevents heart-related complications.
Which region is witnessing the highest demand for ACE inhibitors? +
North America is witnessing the highest demand for ACE inhibitors due to the high prevalence of cardiovascular diseases and hypertension, along with advanced healthcare infrastructure. The aging population in the U.S. and Canada also contributes to increased consumption of these medications.
What are the challenges impacting the ACE Inhibitors Market? +
One of the major challenges facing the ACE Inhibitors Market is the growing preference for alternative therapies such as angiotensin II receptor blockers (ARBs), which are considered to have fewer side effects. Additionally, the patent expirations of leading ACE inhibitors have increased the competition from generic drugs, impacting market revenue.
